Nancy Pelosi has a plan to lower drug prices. The Speaker of the House just released a new bill that would impose a slew of new taxes and allow the government to meddle with private businesses.

We’ve come to expect this type of extremism from Pelosi and House Democrats. Unfortunately, Republicans on the Senate Finance Committee have put forward a strikingly similar plan.

Like Pelosi’s bill, the Senate package would impose new taxes on innovators. While this plan would save the government money in the short-term, it wouldn’t do anything to reduce patients’ out-of-pocket costs. And over time, it would make it harder for researchers to develop new cures.

Much like Pelosi’s bill, the Senate Finance Committee’s package would restructure Medicare’s “Part D” prescription drug benefit. Right now, 45 million Americans rely on Part D for drug coverage.

Rather than administering the benefit itself, the federal government subsidizes private insurers who sell Part D plans to patients. These insurers compete for beneficiaries’ business by offering quality plans at affordable prices.

As a result of this competition, average monthly Part D premiums are around $32 — half of original Congressional Budget Office projection. And nine in 10 seniors are satisfied with their Part D coverage.

Unfortunately, the Senate Finance Committee is willing to compromise this successful program to generate some short-term savings for bean counters at the Treasury Department.

For instance, the bill would penalize drug companies who raise their prices in Medicare faster than the rate of inflation. Firms that defied this edict would have to refund the government the difference between the old and new prices.

This policy is supposed to prevent drug companies from raising prices. But in reality, it would encourage manufacturers to launch medicines at higher list prices, raising costs for beneficiaries. Firms that paid the rebates would have to make up for this lost revenue by slashing their research budgets or shifting costs onto non-Medicare patients.

The bill would also impose a 20 percent manufacturer tax on drugs sold in Medicare’s “catastrophic phase.” Currently, once Part D beneficiaries spend $5,100 out of pocket, the government and their insurer pay for 95 percent of each drug they take. The Senate bill would shift a majority of that burden onto manufacturers. This would cost biotech firms $55 billion over the next decade.

Just like the “inflation penalty,” this new tax would help the government, not patients. If the 20 percent manufacturer liability takes effect, 98 percent of beneficiaries won’t see their out-of-pocket costs drop. Some could even see their pharmacy bills go up.

It’s bad enough that these policies wouldn’t help patients afford their medications. But they would also siphon money away from the search for new treatments.

It takes more than $2.6 billion, on average, for scientists to bring one new drug to market. Research firms rely on revenue from successful drugs to recoup their development costs and fund future endeavors.

The Senate bill’s new taxes would cut into drug makers’ ability to recoup upfront research costs and earn a return. This would make it difficult for these firms to attract investors and continue their groundbreaking research. More than 4,000 drugs currently being developed for Alzheimer’s, cancer and other diseases could die in the lab.

Stifling medical innovation is an expensive mistake. Unless researchers find a new treatment, Alzheimer’s disease alone is expected to cost the United States more than $7 trillion by 2030. Robust drug development is the most effective way to improve patients’ lives, and reduce the burden disease places on our health system.

There’s no doubt that the Senate Finance Committee’s plan would deliver short-term savings to the government. But it would do so at the expense of medical progress, without helping patients at the pharmacy counter.

Join the Conversation

We invite you to use our commenting platform to engage in insightful conversations about issues in our community. Although we do not pre-screen comments, we reserve the right at all times to remove any information or materials that are unlawful, threatening, abusive, libelous, defamatory, obscene, vulgar, pornographic, profane, indecent or otherwise objectionable to us, and to disclose any information necessary to satisfy the law, regulation, or government request. We might permanently block any user who abuses these conditions.

If you see comments that you find offensive, please use the “Flag as Inappropriate” feature by hovering over the right side of the post, and pulling down on the arrow that appears. Or, contact our editors by emailing moderator@scng.com.